Clinical Trial: A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants

U.S., July 31 -- ClinicalTrials.gov registry received information related to the study (NCT07737717) titled 'A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants' on July 27.

Brief Summary: The main objective of this trial is to evaluate the safety and reactogenicity of mRNA-1469

Study Start Date: July 31

Study Type: INTERVENTIONAL

Condition: Ebola-Bundibugyo Virus Disease (Ebola-BDBV)

Intervention: BIOLOGICAL: mRNA-1469

Sterile liquid for injection

BIOLOGICAL: Placebo

Sterile liquid for injection

Recruitment Status: NOT_YET_RECRUITING

Sponsor: ModernaTX, Inc.

Disclaimer: Curated by HT Syndication....